Other

Pfizer Corporation

Klaus Büttner

Renate Sekul

Isabelle Cornut

Jean-Louis Henri Dasseux

Günther Metz

Jean Dufourcq

A device for treating ballast water includes a housing having a ballast water inlet and a ballast water outlet, a hydrocyclone connected to the ballast water inlet and having a particle outlet discharging particles from the device and an outlet carrying particle-depleted ballast water, a filter surrounding the hydrocyclone, which filter divides the device into an intermediate chamber disposed between hydrocyclone and filter and an outer chamber disposed between filter and housing. The intermediate chamber is communicatively connected to the outlet of the hydrocyclone carrying particle-depleted ballast water. Ultrasound is generated to act on the outer chamber and/or the filter, UV light is generated to act on the outer chamber and/or the filter, and a gas is introduced into the outer chamber of the device.

Method for treating ballast water and device for treating ballast water

The present invention provides multimeric apoprotein agonists. Pharmaceutical compositions which include a multimeric apoprotein agonist and a pharmaceutically acceptable carrier, excipient or diluent are also provided. These pharmaceutical are useful to treat a variety of disorders associated with dyslipidemia.

Multimeric apoprotein agonists

The present invention provides peptides and peptide analogues that mimic the structural and pharmacological properties of human ApoA-I. The peptides and peptide analogues are useful to treat a variety of disorders associated with dyslipidemia.

Pharmaceutical compositions of apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Multimeric Apo A-I agonist compounds

Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.

Growing community of inventors

Epfenbach, Germany

Klaus Büttner